Absci (ABSI) Return on Capital Employed (2021 - 2026)
Absci's (ABSI) quarterly Return on Capital Employed came in at 66.39% in Q1 2026, down 860.0% year-on-year from 8.74% in Q1 2025, and down 14.71% quarter-over-quarter from 57.88% in Q4 2025.
Absci (ABSI) Return on Capital Employed (2021 - 2026) Analysis & Trends
Absci has disclosed Return on Capital Employed across 6 years of filings, most recently posting 66.39% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 66.39%, down 860.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 66.39% (down 860.0% YoY), and the FY2025 annual result was 62.6%, down 431.0% from the prior year.
- Return on Capital Employed came in at 66.39% for Q1 2026 at Absci, down from 57.88% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 25.18% in Q1 2022 to a low of 66.39% in Q1 2026.
- The 5-year median for Return on Capital Employed is 51.49% (2023), against an average of 48.18%.
- Across the five-year window, Return on Capital Employed slumped 2297 bps in 2023 and surged 572 bps in 2024, its largest moves.
- Absci's Return on Capital Employed stood at 35.59% in 2022, then slumped by 65 bps to 58.56% in 2023, then climbed by 5 bps to 55.62% in 2024, then retreated by 4 bps to 57.88% in 2025, then dropped by 15 bps to 66.39% in 2026.
- The last three Return on Capital Employed figures came in at 66.39% (Q1 2026), 57.88% (Q4 2025), and 60.21% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Absci | 1.13 Bn | 1.01 Bn | - | -66.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.39% |
| Dec 31, 2025 | -57.88% |
| Sep 30, 2025 | -60.21% |
| Jun 30, 2025 | -62.05% |
| Mar 31, 2025 | -57.79% |
| Dec 31, 2024 | -55.62% |
| Sep 30, 2024 | -47.49% |
| Jun 30, 2024 | -40.99% |
| Mar 31, 2024 | -51.87% |
| Dec 31, 2023 | -58.56% |
| Sep 30, 2023 | -51.49% |
| Jun 30, 2023 | -46.71% |
| Mar 31, 2023 | -36.43% |
| Dec 31, 2022 | -35.59% |
| Sep 30, 2022 | -34.67% |
| Jun 30, 2022 | -30.09% |
| Mar 31, 2022 | -25.18% |
| Dec 31, 2021 | -18.63% |
| Sep 30, 2021 | -16.61% |